Upfront Surgery for Small Intestinal Non-Hodgkin's Lymphoma.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 20 02 2020
revised: 07 03 2020
accepted: 10 03 2020
entrez: 3 4 2020
pubmed: 3 4 2020
medline: 21 4 2020
Statut: ppublish

Résumé

The clinical significance of surgery for secondary small intestinal non-Hodgkin's lymphomas (NHL) remains unknown. This study aimed to investigate the efficacy of resection for both primary and secondary small intestinal NHL. Twenty patients with small intestinal lymphoma who underwent surgical resection at our Institute between 2009 and 2017 were retrospectively evaluated. The clinicopathological and surgery-related factors were reviewed. We also analyzed their surgical outcomes such as postoperative complications, perforation rate, and overall survival (OS). In total, 13 (65%) and 7 (35%) patients had primary and secondary lymphomas, respectively. A total of 70% of patients were diagnosed with aggressive-type lymphomas. A total of 15 (75%) patients had Lugano system stage IV. Only one (5%) patient experienced postoperative grade II deep vein thrombosis and pulmonary embolism. The 3-year OS rate after surgery was 59.6%. Surgical resection prior to chemotherapy is a feasible and safe therapeutic strategy for small intestinal NHL.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
The clinical significance of surgery for secondary small intestinal non-Hodgkin's lymphomas (NHL) remains unknown. This study aimed to investigate the efficacy of resection for both primary and secondary small intestinal NHL.
PATIENTS AND METHODS METHODS
Twenty patients with small intestinal lymphoma who underwent surgical resection at our Institute between 2009 and 2017 were retrospectively evaluated. The clinicopathological and surgery-related factors were reviewed. We also analyzed their surgical outcomes such as postoperative complications, perforation rate, and overall survival (OS).
RESULTS RESULTS
In total, 13 (65%) and 7 (35%) patients had primary and secondary lymphomas, respectively. A total of 70% of patients were diagnosed with aggressive-type lymphomas. A total of 15 (75%) patients had Lugano system stage IV. Only one (5%) patient experienced postoperative grade II deep vein thrombosis and pulmonary embolism. The 3-year OS rate after surgery was 59.6%.
CONCLUSION CONCLUSIONS
Surgical resection prior to chemotherapy is a feasible and safe therapeutic strategy for small intestinal NHL.

Identifiants

pubmed: 32234940
pii: 40/4/2373
doi: 10.21873/anticanres.14206
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2373-2377

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Tetsuhiro Iida (T)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan teyamamoto-tky@umin.ac.jp.

Hiroaki Nozawa (H)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Hirofumi Sonoda (H)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Kazuhiro Toyama (K)

Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.

Kazushige Kawai (K)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Keisuke Hata (K)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Toshiaki Tanaka (T)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Takeshi Nishikawa (T)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Kazuhito Sasaki (K)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Yasutaka Shuno (Y)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Manabu Kaneko (M)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Koji Murono (K)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Shigenobu Emoto (S)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Hiroaki Ishii (H)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Mineo Kurokawa (M)

Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.

Soichiro Ishihara (S)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH